Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3
The stock prices, however, dropped by 3.3 per cent on the BSE at the end of day's trade24-06-2020
24-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to Pre-Clinical Data for GL0034, a new chemical entity, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,24-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for prevention of Insider Trading, the window closure for trading by Designated Persons of the Company shall be with effect from Wednesday, 1st July, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended 30th June, 2020. The date of the Board Meeting of the Company for declaration of the financial results for the quarter ended 30th June, 2020 will be intimated in due course. This is for your information and record.22-06-2020
Sun Pharma, Hikma sign licensing deal for plaque psoriasis drug for MENA region
As per the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply15-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to licensing agreement between Sun Pharma and Hikma for ILUMYA(tm), which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,15-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to clinical insights for ODOMZO(r) and LEVULAN(r) KERASTICK(r), which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,13-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to long term insights into the clinical use of ILUMYA(r), which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,13-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 11, 2020 for Raksha Sudhir Valia11-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 08, 2020 for Shanghvi Finance Pvt Ltd09-06-2020
Buy Sun Pharmaceutical Industries; CMP of Rs 494.25: Equity99
Equity99 is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a CMP price of Rs 494.25 in its research report dated June 08, 2020.09-06-2020